SCHEMBL191817

SCHEMBL191817

Cc1csc(Nc2cc(C(O)c3ccccc3)ccn2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.49
RAB9A P51151 8/20 0.49
NPC1 O15118 8/20 0.49
MEN1 O00255 7/20 0.49
CASP3 P42574 2/20 0.49
SENP8 Q96LD8 2/20 0.49
SENP7 Q9BQF6 2/20 0.49
SENP6 Q9GZR1 2/20 0.49
GAA P10253 5/20 0.49
KCNN1 Q92952 1/20 0.46
KCNN2 Q9H2S1 1/20 0.46
KCNN3 Q9UGI6 1/20 0.46
SLC2A1 P11166 1/20 0.46
POLB P06746 3/20 0.44
GCK P35557 2/20 0.43
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CCR4 P51679 1/20 0.41
ALDH1A1 P00352 2/20 0.40
MAPT P10636 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL190631 0.77 KMT2A (0.50) KMT2ARAB9ANPC1MEN1CASP3
SCHEMBL190466 0.76 NPC1 (0.57) KMT2ARAB9ANPC1MEN1CASP3
SCHEMBL190694 0.76 GCK (0.54) KMT2ARAB9ANPC1MEN1CASP3
SCHEMBL12305671 0.76 RAB9A (0.53) KMT2ARAB9ANPC1MEN1CASP3
SCHEMBL190659 0.75 GCK (0.59) KMT2ARAB9ANPC1MEN1CASP3
Hydrochloric Acid SCHEMBL190582 0.75 RAB9A (0.52) KMT2ARAB9ANPC1MEN1CASP3
SCHEMBL12215995 0.74 RAB9A (0.65) KMT2ARAB9ANPC1MEN1CASP3
SCHEMBL190581 0.73 KMT2A (0.49) KMT2ARAB9ANPC1MEN1CASP3
SCHEMBL192197 0.73 NPC1 (0.47) KMT2ARAB9ANPC1MEN1CASP3
SCHEMBL191180 0.72 GCK (0.60) KMT2ARAB9ANPC1MEN1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 KMT2A 2715/4885RAB9A 1808/4885NPC1 1862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.